The yeast protein Taz1 is the orthologue of human Tafazzin, a phospholipid acyltransferase involved in cardiolipin (CL) remodeling via a monolyso CL (MLCL) intermediate. Mutations in Tafazzin lead to Barth syndrome (BTHS), a metabolic and neuromuscular disorder that primarily affects the heart, muscles, and immune system. Similar to observations in fibroblasts and platelets from patients with BTHS or from animal models, abolishing yeast Taz1 results in decreased total CL amounts, increased levels of MLCL, and mitochondrial dysfunction. However, the biochemical mechanisms underlying the mitochondrial dysfunction in BTHS remain unclear. To better understand the pathomechanism of BTHS, we searched for multi-copy suppressors of the taz1Δ growth defect in yeast cells. We identified the branched-chain amino acid transaminases (BCATs) Bat1 and Bat2 as such suppressors. Similarly, overexpression of the mitochondrial isoform BCAT2 in mammalian cells lacking TAZ improves their growth. Elevated levels of Bat1 or Bat2 did not restore the reduced membrane potential, altered stability of respiratory complexes, or the defective accumulation of MLCL species in yeast taz1Δ cells. Importantly, supplying yeast or mammalian cells lacking TAZ1 with certain amino acids restored their growth behavior. Hence, our findings suggest that the metabolism of amino acids has an important and diseaserelevant role in cells lacking Taz1 function.
Introduction
Mitochondria are essential organelles that fulfill crucial roles in cellular bioenergetics, apoptosis, and metabolism of amino acids, lipids, nucleic acids, and heme. To properly carry out all these functions, mitochondria have to maintain their unique protein and lipid composition. Of the mitochondrial lipids, cardiolipin (CL) comprises the signature dimeric phospholipid (PL) for this organelle. CL interacts with several inner membrane (IM) protein complexes affecting the structure and activity of respiratory supercomplexes and ultimately the oxidative generation of ATP [29, 46] . In addition, CL has been implicated in the biogenesis of outer membrane proteins [16, 31] .
After its initial synthesis, CL undergoes acyl chain remodeling that replaces the pre-existing fatty acids with other ones, which are organism and tissue-specific [34] . This reaction is catalyzed by the enzyme TAZ (Tafazzin) that encodes a PL transacylase, which is highly conserved from yeast to human.
Mutations in the Tafazzin gene are associated with a number of clinical disorders including Barth syndrome (BTHS).
BTHS is a rare X-linked disease characterized by skeletal myopathy and cardiomyopathy, and in some cases, neutropenia. Although three CL remodeling pathways have been identified in higher eukaryotes, TAZ1 is the only transacylase that mediates such remodeling in yeast cells [10] . Loss of Taz1 leads to a decrease in the total cellular amounts of CL, accumulation of monolyso-cardiolipin (MLCL, CL lacking one acyl chain), and aberrant CL species [19] . Similar alterations were also observed in fibroblasts and platelets obtained from either patients with BTHS or animal models [33, 39, 41] . Despite the aforementioned CL-related disturbances, it was reported that the major phenotypes of yeast cells lacking TAZ1 are mainly due to the increased ratio MLCL/CL rather than the absence of modified CL [2, 44] . In addition to the altered CL composition, a multitude of various mitochondrial defects is observed in cells lacking TAZ1. Mitochondria of yeast taz1Δ cells also exhibit a decreased membrane potential and increased proton leak [1] . Such a hampered proton-motive force across the IM aggravates mitochondria function, and the organelles are then prone to oxidative damage by the increased production of reactive oxygen species (ROS).
One of the main metabolic pathways that take place inside mitochondria is the tricarboxylic acid (TCA) cycle, which is crucial for providing reductive equivalents to the respiratory chain complexes. In cells defective for TAZ1, the ATP production via oxidation of NADH is compromised, resulting in a decreased NAD + /NADH ratio [18] . As a consequence of the NADH accumulation, metabolic dysfunctions such as inhibition of TCA cycle enzymes that require NAD + occur, and subsequently, the TCA cycle activity halts [20, 40] .
Although TAZ mutations have been clearly implicated in BTHS, the precise role and the involvement of this protein in the pathomechanism of the disease have remained elusive. To address this issue, we screened for multi-copy suppressors of the taz1Δ growth defect in yeast cells and identified the branchedchain amino acid transaminases (BCATs), Bat1 and Bat2, as such suppressors. Accordingly, we found that altered metabolism of amino acids likely plays an important and disease-relevant role in human cells lacking TAZ. Collectively, our findings provide insights to the pathomechanism of the TAZ-mediated BTHS.
Results
Identification of multi-copy suppressors for impaired growth of taz1Δ cells Yeast cells provide a reliable model system to study the pathomechanism of BTHS. The deletion of TAZ1 does not lead to observable growth defects on synthetic medium containing a fermentable carbon source like glucose (SD) or non-fermentable ones like glycerol or acetate (SG or SA, respectively). In contrast, cells lacking Taz1 grow poorly when ethanol is the sole carbon source (Fig. 1a , SE-Leu). This growth defect can be reversed upon expression of TAZ1 from a plasmid (Fig. 1a) , suggesting that the absence of Taz1 is the primary reason for this defect. To better understand the molecular mechanisms involved in this phenotype, we searched for gene targets whose overexpression suppresses the growth defect of taz1Δ cells. For this purpose, we transformed taz1Δ cells with a yeast genomic library cloned in a high copy number (2μ based) yeast expression vector [35, 37] . Transformants were initially grown on selective medium lacking uracil (SD-Ura) to select for those containing the plasmid and then replica-platted several times on plates containing ethanol (SE-Ura), condition where taz1Δ cells do not grow. Clones able to grow on ethanol as the sole carbon source were considered as those harboring potential suppressors (Fig. 1b) . To ensure saturation, we screened 55,000 colonies and identified several clones that exhibited rescue of the growth defect.
One of the identified clones contained the TAZ1 open reading frame (ORF) (data not shown), confirming the validity of the screen. The remaining plasmids harbored DNA fragments mostly co-encoding for CRG1, COX24, HMX1, and BAT1 (Fig. 1b,  #16 and #29). CRG1 encodes for a methyltransferase involved in lipid homeostasis, Cox24 is a translation modulator of COX1 mRNA, and Hmx1 is an ER heme oxygenase, whereas BAT1 encodes for a mitochondrial BCAT [25] . To verify the potential of these genes to complement the growth defect, they were genomically overexpressed in taz1Δ cells under the control of the strong GPD promoter. Growth assessments of the four initial candidates demonstrated that only BAT1 overexpression was able to reproducibly rescue the taz1Δ growth defect (Fig. 1c,  d ). Since Bat1 has a highly homologous protein, Bat2, which shares the same function but is located in the cytosol [25] , we analyzed whether the overexpression of BAT2 can also complement the growth defect of taz1Δ cells. Indeed, the overexpression of BAT2 rescues the growth defect of taz1Δ cells, though not as efficient as the overexpression of BAT1 (Fig. 1d) .
Western blotting analysis verified that indeed Bat1 and Bat2 are detected in higher levels in the overexpressing strains (Fig. S1 ). Given the high sequence homology between Bat1 and Bat2, the antibody raised against Bat1 also recognizes Bat2. Interestingly, it appears that Bat1 levels are decreased in bat2Δ cells (Fig. S1 ).
The rescue of the growth defect of taz1Δ cells by BAT1 or BAT2 overexpression suggests a functional compensation related to the defective CL remodeling process. To address whether the observed compensation can be also extended to the loss of CL, we analyzed the growth of cells deficient for CL due to deletion of key enzymes in its biosynthesis pathway, GEP4 and CRD1. These mutant cells have a severe growth defect when incubated at elevated temperatures on non-fermentable carbon sources. In contrast to the situation with taz1Δ cells, we did not observe rescue of the growth defects of cells lacking CL biosynthetic enzymes upon BCATs overexpression (Fig. 1e) . These results indicate that enhanced metabolism of amino acids can compensate for defects specifically related to CL remodeling but not to its absence.
BCAT-mediated rescue of the retarded growth of taz1Δ cells is not associated with repair of known mitochondrial defects in these cells CL is known to stabilize the electron transport chain supercomplexes [3, 26, 46] . Accordingly, the formation of supercomplexes harboring complexes III and IV is altered in mitochondria lacking Taz1 [2, 6] (Fig. 2a, b) . To understand better the relevance of BCATs for the rescue of taz1Δ growth defect, we investigated whether their overexpression could restore this altered assembly. Upon analyzing complexes assembly by blue native (BN)-PAGE, we found that overexpression of neither BAT1 nor BAT2 reverted the defects caused by loss of Taz1 to the assembly of respiratory chain complexes (Fig. 2a, b) . More generally, loss of Taz1 leads to reduced membrane potential (ΔΨ) by~30%, as compared to WT mitochondria [6] . Overexpression of BCATs did not restore the reduced ΔΨ of mitochondria isolated from taz1Δ cells, as monitored with the membrane potential-sensitive dye 3,3′-diprophylthiadicarbocyanine iodide (DiSC 3 (5)) (Fig. 2c) .
Next, we measured the oxygen consumption of mitochondria isolated from either control (WT) or taz1Δ cells. Interestingly, mitochondria of the mutant cells had higher consumption rate, maybe in an attempt to compensate their compromised function. The overexpression of BAT1 or BAT2 in taz1Δ cells reverts the oxygen consumption to WT levels (Fig. S2a) . Hence, BAT1/2 can affect respiration without correcting the ΔΨ and the respiratory chain supercomplexes assembly. As a comparison, deleting the TCA enzyme Fumarase resulted also in enhanced oxygen consumption, whereas, as expected, the absence of the mitochondrial IM insertase Oxa1 led to highly reduced respiration (Fig. S2b) .
We wondered if the capacity to affect the respiration resulted from a rescue of the lipid content of mitochondria. A major consequence of the loss of Taz1 function is a decrease in the amounts of CL and accumulation of MLCL species [43] . Therefore, we investigated by thin-layer chromatography (TLC) the effect of BAT1/2 overexpression on the PL profile of mitochondria isolated from taz1Δ cells. As expected, MLCL a WT and taz1Δ cells were grown at 30°C in liquid medium and then five-fold serial dilutions were spotted on synthetic medium containing glucose (SD), glycerol (SG), or acetate (SA). WT and taz1Δ cells transformed with an empty plasmid (Ø) as well as taz1Δ cells expressing plasmid-born TAZ1 were cultured as above and spotted on ethanolcontaining synthetic medium lacking leucine (SE-Leu). b taz1Δ cells were transformed with the empty plasmid pFL44L, a plasmid encoding TAZ1 (pYX142-TAZ1), or with plasmids of the genomic library isolated from positive candidates of the screen (#13, 15, 16, 29, two colonies each). Cells were analyzed by drop dilution assay on SE medium at 30°C. Plasmid #16 harbors BAT1 and CRG1 whereas #29 harbors COX24 and HMX1. c WT and taz1Δ cells genomically overexpressing COX24, CRG1, or HMX1 were analyzed at 30°C by drop dilution assay on SE medium. d WT and taz1Δ cells as well as taz1Δ cells genomically overexpressing either BAT1 or BAT2 were analyzed by drop dilution assay at 30°C on SE medium. e WT, gep4Δ, or crd1Δ cells as well as gep4Δ and crd1Δ cells genomically overexpressing either BAT1 or BAT2 were analyzed by drop dilution assay at 37°C on YPG medium or at 30°C on YPD medium accumulation and CL reduction were observed in mitochondria lacking Taz1. However, elevated levels of Bat1 or Bat2 did not rescue this altered PLs profile (Fig. 2d ). This suggests that recovery of respiration behavior is not through a rescue of lipid homeostasis but through a bypass mechanism. In accordance with this notion, we found that overexpression of BAT1/2 does not affect the steady state levels of proteins residing in the various mitochondrial sub-compartments (Fig. 2e ).
Amino acid supplementation rescues the growth defect of taz1Δ cells
Bat1 and Bat2 are branched-chain amino acid aminotransferases that catalyze the conversion of branched-chain amino acids (BCAAs) and α-ketoglutarate into branched-chain α-keto acids and glutamate. We next asked whether supplementation of BCAAs to the medium could rescue the growth retardation of taz1Δ cells. Indeed, supplementation of valine rescued the growth defect of taz1Δ cells in a dose-dependent manner (Fig. 3a) . However, the addition of the two other BCAAs, leucine (Fig. S3a) or isoleucine ( Fig. S3d) , did not result in improved growth of taz1Δ cells. Along the same line, overexpression in the mutated cells of the LEU2 gene, which encodes a key enzyme in the biosynthesis pathway of leucine, did not rescue the growth defect (Fig. S3b) . Since the BCAT enzymes can catalyze the conversion between keto acids and amino acids in both directions, we also tested whether the corresponding keto acid form of leucine, alpha-ketoisocaproic acid (KIC), might have a beneficiary effect for taz1Δ cells. However, addition of this molecule to the solid medium did not improve the growth of the mutated cells (Fig. S3c) .
To test whether other amino acids can rescue the defects of Taz1-deficient cells, we supplemented ethanolcontaining plates with aspartate. Of note, the growth defect of taz1Δ cells was largely rescued upon supplementation with this amino acid (Fig. 3b) . To investigate if the observed rescue of the growth defect is related to the CL profile of these cells, we analyzed the profile of PLs of Fig. 2 Overexpression of BAT1 or BAT2 does not rescue several defects of taz1Δ cells. a, b Mitochondria isolated from the indicated strains were lysed with 1% digitonin and subjected to a 6-14% BN-PAGE. Proteins were analyzed by immunodetection with an antibody against either Rip1, a subunit of complex III (a), or Cox2, a subunit of complex IV (b). Supercomplexes of the respiratory chain complexes are indicated. c Membrane potential (ΔΨ) of mitochondria isolated from the indicated strains was determined by a fluorescence assay. The fluorescence signal of control organelles was set to 100%. Average values ± S.D. of three independent experiments are shown. d Lipids extracted from the mitochondrial fraction of the indicated cells were analyzed by TLC and staining with molybdenum blue. The migration behavior of standard phospholipids is indicated. e The indicated amounts of mitochondria isolated from the specified strains were analyzed by SDS-PAGE and immunodecoration with the indicated antibodies isolated mitochondria from taz1Δ cells grown in the absence or presence of either aspartate or valine (Fig. 3c) . Our results revealed that supplementation of taz1Δ cells with both amino acids did not restore the defective MLCL/CL ratio characteristic for these mutated cells.
We expanded our analysis also to supplementation with either glutamate or histidine. Whereas the former amino acid only rescues partially the decreased growth of taz1Δ cells (Fig. 3d) , addition of histidine to the medium could fully restore the growth deficit of taz1Δ cells (Fig. 3e) . Taken together, these results show that the Bat1/2-mediated rescue of Taz1-depleted cells can be explained by elevated cellular levels of some amino acids. Our findings that elevated levels of BCATs or supplementation of certain amino acids can rescue the growth defect of taz1Δ cells led us to investigate whether enhanced transport of amino acids from the vacuole (yeast lysosome) to cytosol can have a similar effect. To that aim, we overexpressed two vacuolar amino acid transporters AVT1 and AVT4 in the mutated cells. However, such overexpression did not improve the growth of taz1Δ cells (Fig. 3f) .
Increased levels of TCA cycle metabolites and amino acids in taz1Δ cells with elevated amounts of Bat1
The previous results suggested that overexpression of BCATs or supplementation of amino acids like valine, aspartate, glutamate, or histidine can rescue the growth defects of taz1Δ cells. Hence, we tested whether the levels of these amino acids or metabolites of the TCA cycle are actually altered in the deletion cells and if the overexpression of BCATs changes their levels. To that end, we grew the cells in 2% ethanol, extracted metabolites from yeast cells, and monitored their levels by liquid chromatography coupled with mass spectrometry (LC-MS). The amounts of most of the TCA cycle intermediates were reduced in taz1Δ cells (Fig. 4 ). Yet, we did not observe a restored growth of taz1Δ cells upon supplementation of TCA metabolites (Fig. S4) . Importantly, we observed that BAT1 overexpression restores and even greatly increased the levels of most of the TCA metabolites and of the beneficial amino acids like valine and histidine (Fig. 4) . In agreement with its reduced rescue capacity, overexpression of BAT2 did not have a significant effect on the levels of these metabolites (Fig. 4) . These results support the notion that reduced levels of certain amino acids can contribute to the cellular defects in taz1Δ cells and replenishing these metabolites can rescue the growth retardation of these cells.
Overexpression of mammalian BCATs or valine supplementation enhances the proliferation of Tafazzin-deficient mouse embryonic fibroblasts
The aforementioned results were obtained with a yeast model of BTHS. To generalize our hypothesis and substantiate our findings, we turned to mammalian cells. We employed our 
were analyzed by drop dilution at 30°C on SE medium previously described mouse embryonic fibroblasts (MEFs) where Tafazzin was knocked-out (TAZ −/− ) [9] . We found that the overexpression of the mammalian mitochondrial isoform BCAT2 [4] provides a significant increment of proliferation for cells lacking TAZ (Fig. 5a ). In contrast, elevated levels of the cytosolic form, BCAT1, had only minor effect on the growth of the mutated cells. Of note, overexpressing BCATs in WT cells did not influence the growth of these cells (Fig. 5a) . Next, we sought to test the effect of valine supplementation on proliferation of TAZ −/− cells and observed a major enhancement already at rather low concentrations of valine supplementation (1 mM) (Fig. 5b) . Analysis of growth after 72 h revealed that the addition of valine to the growth medium resulted in a threefold increase in cell proliferation of the mutant cells, whereas that of control cells was increased only slightly. These findings indicate that the ability to rescue the growth of TAZ mutant by either overexpression of mitochondrial BCAT or by supplementation of certain amino acids is conserved from yeast to mammalian cells.
Discussion
The deletion of TAZ1 leads to a severe growth phenotype of yeast cells on synthetic medium using the non-fermentable carbon source ethanol as the sole carbon source. Of note, these mutant cells grow normally on non-fermentable carbon sources like glycerol or acetate suggesting that compromised respiration is not the main problem of these cells. Indeed, our results suggest increased respiration in these cells. The sensitivity of the taz1Δ mutant to ethanol is consequential of the decreased CL levels and altered acyl composition of this crucial dimeric PL. As previously reported, ethanol-tolerance of mutants in yeast depends on their lipid composition and unsaturation degree [8] .
Mitochondrial damage occurs upon ethanol stress via inactivation of some mitochondrial enzymes and increased production of ROS [11, 13, 22] . In fact, it has been shown that in taz1Δ cells grown in ethanol, the carbonylation levels of proteins-an indicative of increased ROS-are double than those of cells grown on glucose [7] . Thus, the various compromised mitochondrial functions in taz1Δ cells aggravate their ethanol sensitivity.
In the current study, we report on BCATs as specific suppressors of the growth defects of both yeast and mammalian cells lacking Taz1 or TAZ, respectively. We identified this new property for Bat1 and Bat2 while searching for highcopy suppressors of the growth phenotype of yeast taz1Δ cells. Despite its reasonable growth phenotype suppression Fig. 4 The levels of some metabolites are altered in taz1Δ cells and restored upon overexpression of BAT1. The indicated metabolites were extracted from the specified cells grown in ethanol-containing medium and were analyzed by LC-MS. The relative peak area of each metabolite was determined, and the levels in control WT cells were taken as 100%. Mean values ± S.D. of six independent experiments are shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001 capacity, the cytosolic protein Bat2 was not identified in the multi-copy suppressor screen, probably due to incomplete coverage of the used genomic library. Of note, the overexpression of BCATs could not rescue the growth defects of cells lacking CL all together, suggesting that the products of their enzymatic activities cannot complement the absence of this unique PL. Both BCATs were reported previously to affect directly or indirectly several cellular processes. For example, BAT1, but not BAT2, was identified as a high-copy suppressor of a temperature-sensitive mutation in ATM1, encoding a mitochondrial ABC transporter [25] . Recently, both yeast BCAT homologs have been implicated to be critical for the activation of TORC1 signaling [24] . Hence, these aforementioned observations together with our current findings that supplementation of taz1Δ cells with amino acids reversed their compromised proliferation suggest that enhanced metabolism of amino acids might compensate for other cellular dysfunctions.
Overexpression of the BCATs does not restore mitochondrial defects reported for taz1Δ cells like altered assembly of respiratory complexes, increased MLCL/CL ratio, or reduced membrane potential. On the other hand, such overexpression increases the levels of some TCA metabolites. Hence, our findings suggest that the major contribution of BCATs is probably through a compensatory increase in the flux of the TCA cycle. Interestingly, the growth defect rescue in both yeast and mammalian cells with the two different BCAT isoforms was similar. In both cell types, the mitochondrial isoform had a higher rescue capacity. Hence, although the mitochondrial and cytosolic isoforms have overlapping functions in transamination reactions, it appears that their products are required more in mitochondria and that they are not completely free to equilibrate between the matrix of mitochondria and the cytosol.
An interesting question is why only valine among the BCAAs and other amino acids like aspartate or histidine displayed rescue activity on taz1Δ cells. Obviously, it is hard to determine how much of the externally added metabolites are actually transported across the cell wall, plasma membrane, and into the mitochondrial matrix. Hence, we cannot exclude the obvious possibility that differences in rescue ability reflect (at least partially) variations in the transported amounts (and hence effective concentrations) of the different molecules. An alternative explanation is that in contrast to the two other BCAAs, valine degradation products can be fed directly into the TCA cycle, leading to a faster replenishment of the cellular energy demands.
Currently, despite the obvious link to the TCA cycle, the mechanism by which overexpression of BCATs and elevated levels of certain amino acids rescue the growth defects of cells lacking Taz1 is not completely clear. One possibility is that the enhanced levels of either amino acids or TCA metabolites can serve as replenishment for amino acids or metabolites, which their formation is compromised in taz1Δ cells. An alternative, but not mutual exclusive possibility, is that the backbones of these amino acids, which contain more than two carbons (in contrast to ethanol), are used for general carbon anabolic pathways (like gluconeogenesis).
In addition, beneficial effects of amino acids were reported in several related contexts. For example, dietary supplementation of BCAAs has been implied to protect against ethanol toxicity by reverting structural and functional mitochondrial damages in rodents with alcoholic liver disease [38] . A link between impaired CL remodeling and amino acids metabolism is further supported in a TAZ knock-down mouse model in which the increased MLCL/CL ratio led to a substrate shift via de novo amino acid biosynthesis as well as amino acid usage by the TCA cycle [23] . Additionally, Bat1 was reported to interact with the TCA cycle enzyme aconitase. The recent identification of yeast oxodicarboxylate carrier (Odc1) as another factor that can rescue defects of taz1Δ cells [36] further support the link between amino acids metabolism and taz1Δ phenotypes. Odc1 is involved in glutamate and lysine biosynthesis by its function as a transporter of several TCA cycle intermediates across the mitochondrial IM [28] . Elevated levels of Odc1 were reported to fully restore the oxidative phosphorylation and growth defects in taz1Δ yeast cells [36] .
Furthermore, mutation of BCATs resulted in perturbed TCA-cycle intermediate levels, which in turn led to reduced ATP levels and inhibition of TORC1 [24] . Another evidence for the potential relevance of CL for the TCA cycle emerges from a recent study showing that yeast cells deleted for CL synthase (crd1Δ), and hence are CL-deficient, have decreased acetyl-CoA levels, decreased activity of acetyl-CoA synthetase, and consequently, deficiencies in the TCA cycle. These defects were reflected in decreased growth on medium containing acetate as the sole carbon source [30] . Interestingly, the taz1Δ strain displays no growth defect on acetate media, a phenotype that is characteristic for many yeast mutants bearing disruptions in genes encoding TCA cycle enzymes [27] . Thus, although we observed lower levels of some TCA cycle metabolites in taz1Δ cells, it is unclear to which extent the TCA cycle is compromised in these cells. Naturally, one cannot exclude the contribution of peroxisomes in providing new TCA cycle intermediates by β-oxidation or the glyoxylate cycle [14] . Yet, we propose that peroxisomal function is not related to the phenotypes of taz1Δ cells, since these cells grow normally on medium containing oleic acid as the sole carbon source (data not shown), conditions where yeast cells rely on functional peroxisomes.
Collectively, we suggest that elevated levels of certain amino acids can enhance cellular growth either directly upon their conversion to TCA intermediates and increased flux of this pathway or indirectly by their induction of the mTOR signaling pathway. Taken together, we show here that yeast and mammalian cells lacking CL remodeling benefit from the overexpression of BCATs and valine supplementation. As such, this work proposes that the metabolism of amino acids has an important and disease-relevant role in such mutated cells and highlights the potential usage of some amino acids as a therapeutic avenue to help alleviate some of the symptoms of patients with BTHS.
Materials and methods

Yeast strains and growth conditions
The wild type Saccharomyces cerevisiae W303α or BY4741 strains were utilized. Cells were transformed using the Li-acetate method [17] . Genomic overexpression was performed by homologous recombination replacing the endogenous promoter by the constitutive promoter GPDpr [21] . Primers for these replacements and their validation were designed using the Primers-4-Yeast toolkit [45] . To delete complete ORFs by homologous recombination, the HIS3MX6 cassette was amplified from the plasmid pFA6a-HIS3MX6 [42] with gene-specific primers. Yeast strains used in this study are described in Table S1 . For drop dilution assays, cells were cultured to logarithmic phase, collected by centrifugation, and resuspended in water to an OD 600 of 2.0. Cell suspensions were serially diluted fivefold in water, and 5 μl of each cell suspension was spotted on the appropriate solid medium followed by incubation at either 30 or 37°C. In some cases, the indicated concentrations of the specified metabolite were added to SE solid medium.
Recombinant DNA techniques
The ORF of TAZ1 was amplified by PCR from WT yeast genomic DNA and cloned into the plasmid pYX142 using EcoRI and HindIII restriction sites. The construct was verified by DNA sequencing. A list of all plasmids and primers used in this study is included in Table S2 .
Multi-copy suppressor screening
Electro-competent yeast cells lacking Taz1 (taz1Δ) were transformed with a high-copy-number yeast genomic library in the URA3 2μ plasmid pFL44L [35] . To select for transformants, cells were initially grown at 30°C on SD lacking uracil (SD-Ura). Then, clones were replica plated several times on SE medium and further incubated at 30°C. Plasmid DNA was extracted from clones that grew under these conditions and transformed into E. coli cells. Plasmids were obtained from the transformed E. coli cells and their capacity to rescue the growth defect of taz1Δ cells was confirmed. The DNA inserts of isolated verified plasmids were identified by sequencing.
Biochemical methods
Mitochondria were isolated from yeast cells grown to logarithmic phase in either lactate or S-lactate medium and harvested by differential centrifugation as described [12] . To analyze the steady state levels of mitochondrial proteins, isolated organelles were subjected to 12.5% or 10% SDS-PAGE and proteins were transferred onto nitrocellulose membranes by semi-dry western blotting. Proteins were immunodecorated with primary antibodies and the detection was performed with horseradish peroxidase-coupled secondary antibody. A list of primary antibodies used in this study is included in Table S3 .
Blue Native (BN)-PAGE was performed as described before [32] . Briefly, mitochondria were solubilized in 40 μl buffer containing digitonin (1% digitonin, 20 mM Tris-HCl, 0.1 mM EDTA, 50 mM NaCl, 10% (v/v) glycerol, 1 mM PMSF, pH 7.2). After incubation on ice for 15 min and clarifying spin (30,000 g, 15 min, 2°C), 5 μl sample buffer (5% (w/v) Coomassie blue G, 500 mM 6-amino-N-caproic acid, 100 mM Bis-Tris, pH 7.0) was added. The native complexes were analyzed by electrophoresis in a 6-14% gradient of acrylamide BN-PAGE gel. Gels were blotted on polyvinylidene fluoride membranes and proteins were further analyzed by immunodecoration.
Monitoring membrane potential of isolated mitochondria
The membrane potential across the mitochondrial IM (ΔΨ) was monitored by fluorescence quenching of a ΔΨ-sensitive dye by adapting a published method [15] . Briefly, DiSC3(5) (final concentration of 2 μM) was added to 3 ml buffer containing (0.6 M sorbitol, 0.1% (w/v) fatty acid-free BSA, 0.5 mM EDTA, and 20 mM KPI, pH 7.2. The fluorescence was monitored with excitation at 622 nm and emission at 670 nm, and data points were taken at 2 s intervals. Once the fluorescence signal was stabilized, 50 μg of isolated mitochondria was added to the cuvette, and the fluorescence intensity was further monitored until a stable signal was obtained. Finally, to completely dissipate the membrane potential, valinomycin (final concentration 1 μM) was added to the mixture, and the increase in the fluorescence intensity was recorded. Membrane potential was assessed as the difference between the fluorescence signal before and after the addition of valinomycin.
Mitochondrial oxygen consumption assay
The rate of oxygen consumption of isolated mitochondria was measured polarographically at 25°C using a Clark-type oxygen electrode connected to a computer-operated Oxygraph control unit (Hansatech Instruments, Germany). Isolated mitochondria (100 μg) suspended in a buffer containing 0.6 M sorbitol, 20 mm Hepes (pH 7.4), 1 mM EDTA, and 1 mM MgCl 2 were added to the oxygen chamber with continuous stirring. Respiration was initiated by the addition of NADH (final conc. 7 mM) and recorded at sampling intervals of 1 s (Oxygraph Plus software, Hansatech Instruments).
Extraction and analysis of mitochondrial phospholipids
Lipid extraction of isolated mitochondria was performed according to published method [5] . Briefly, a mixture of chloroform:methanol 1:2 (v/v) was added to 600 μg of mitochondria, vortexed, and incubated on ice for 30 min. Then, 1.25 times (v/v) of chloroform followed by 1.25 times (v/v) of water were added, with vigorous vortex after each addition, and samples were centrifuged (1000 g, 5 min, RT). The organic phase was collected, and solvents were evaporated by SpeedVac. Then, lipids were resuspended in 40 μL of chloroform:methanol 1:1 (v/v) mixture and either stored at − 20°C or immediately used.
PL classes from the total lipid extract were separated by TLC using glass plates of pre-coated 0.25-mm silica gel with fluorescent indicator UV 254 . Prior to separation, the silica plates were washed with a mixture of chloroform:methanol 1:1 (v/v) and dried for 15 min. Then, plates were sprayed with a solution of 2.3% (v/v) boric acid in ethanol and dried in an oven at 100°C for 15 min. Next, 40 μL of sample of total lipid extract or 3-5 μL of PL standards was applied to the plate. The spots were air dried and developed in a solvent mixture of chloroform/ethanol/water/trimethylamine (30:35:7:35, v/v/v/v). After complete migration and eluent evaporation, the TLC plates were sprayed with molybdenum blue solution. Identification of the different classes of PLs was performed by comparison with the migration behavior of PL standards.
Analysis of yeast metabolites by mass spectrometry
Pellets of yeast cells were lyophilized followed by homogenization with a ball mill. Metabolites were first extracted with 400 μl of 80% methanol containing 0.1% formic acid and afterwards re-extracted with 400 μl of 20% methanol containing 0.1% formic acid. Both supernatants were combined and dried in a SpeedVac concentrator. Samples were re-dissolved in 120 μl of 20% methanol containing 0.1% formic acid, and 7 μl was injected onto a Waters Acquity HSST3 2.1 × 100 mm, 1.8-μm ultra-performance liquid chromatography (UPLC) column. Separation was carried out with an isocratic 2-min step of 99% water containing 0.1% formic acid, followed by a linear 10-min gradient to 99% methanol (containing 0.1% formic acid) at a flow rate of 200 μl/min. The analysis was conducted with a Waters Acquity UPLC-SynaptG2 LC/ MS system operated in positive and negative electrospray ionization mode with a scan range of 50-2000 m/z at a scan rate of 0.5 s. For relative quantification of the metabolites, extracted ion traces were generated and integrated.
MEF cell culture, transfection, and cellular proliferation measurements WT and TAZ KO MEF cells (as described in Ref. 9) were cultured at 37°C under a 5% CO 2 humidified atmosphere in Dulbecco's modified eagle medium (DMEM) supplemented with 10% [v/v] fetal bovine serum (FBS) (GIBCO, Invitrogen). Cell growth kinetics was studied under different growth conditions by plating 1 × 10 5 cells in media containing 0.9-g/L galactose. Cell counts were performed using a hemocytometer at the interval of 24 h. In some cases, the indicated concentration of valine was added to the medium.
The transfection of WT and TAZ KO MEF cells (1 × 10 7 ) was performed by electroporation with 20-μg empty pCDNA5.1 plasmid or pCDNA5.1 containing the cDNA of either BCAT1 or BCAT2 at 1350 V with a single pulse of 30 ms using the Neon Transfection System (Thermo Fisher Scientific). Immediately after the electroporation, the cells were plated in glucose-containing media for 24 h. Next, 2.5 × 10 5 cells of each experimental condition were re-plated in galactose-containing media for cell counts.
